TempraMed to Support Beyond Type 1's Beyond Type Run Team at the 2025 TCS New York City Marathon
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") the innovator behind the VIVI product line of temperature-protective solutions for injectable medications, is proud to announce its in-kind partnership of Beyond Type 1's 2025 TCS New York City Marathon initiative, Beyond Type Run. Through this partnership, TempraMed joins Beyond Type 1 in empowering 55 inspiring
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-27 7:00 AM EDT | TempraMed Technologies Ltd
DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce, further to its press release from June 3, 2025, its previously announced non-brokered private placement of units ("Units") at a price of $0.50 per Unit has been increased to up to 2,000,000 units for aggregate gross proceeds of $1,000,000 (the "Offering"). Each Unit will consist
2025-10-24 8:37 AM EDT | DiagnosTear Technologies Inc.
The Gourmet Gifts Expands 2025 Corporate & Holiday Gifting Collection
Toronto, Ontario--(Newsfile Corp. - October 23, 2025) - The Gourmet Gifts, a trusted Canadian luxury gifting firm, today released its 2025 Holiday Collection. With its premium, thoughtfully curated gift baskets and hassle-free delivery, the company is further establishing itself among corporate customers as well as individual consumers. "We
Internet Technology, Pharmaceuticals, Publishing / Informational Services, Health
2025-10-23 10:04 AM EDT | BrandingEx Solutions Pvt Ltd.
Izotropic CEO Interview: IzoView Differentiators, Regulatory Plans, and Outlook
Sacramento, California--(Newsfile Corp. - October 23, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of a new video interview
2025-10-23 8:00 AM EDT | Izotropic Corporation
Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technology in enhancing the efficacy of antibody-drug conjugates (ADCs) at the 16th World ADC Conference in San Diego, CA, USA
Biotechnology, Pharmaceuticals, Health
2025-10-23 3:15 AM EDT | Defence Therapeutics Inc.
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce that the Government of Japan has
Biotechnology, Pharmaceuticals, Health
2025-10-22 10:04 AM EDT | Hemostemix Inc.
DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "X8F." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 6 months, commencing on October 21, 202
2025-10-22 8:35 AM EDT | DiagnosTear Technologies Inc.
FendX Files Provisional Patent for Novel Antimicrobial Nanoparticle Liquid Coating
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office. The application, titled "Antimicr
Technology, Healthcare and Hospitals, Health
2025-10-22 6:00 AM EDT | FendX Technologies Inc.
Adia Nutrition Inc. Appoints Dr. Evan Thomas, MD, PhD, to Drive Adia Med's Specialized Treatment Revolution
Winter Park, Florida--(Newsfile Corp. - October 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is excited to announce the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider st
Healthcare and Hospitals, Health
2025-10-21 9:00 AM EDT | Adia Nutrition Inc.
Hear At Last Signs Exclusive Contract with Hebei Jiachen Integrated Housing Co. for Affordable Modular Homes in North and Central America as Well as the Caribbean
Miami, Florida--(Newsfile Corp. - October 21, 2025) - Hear At Last (OTCID: HRAL), a leader in innovative housing solutions, is pleased to announce an exclusive partnership with Hebei Jiachen Integrated Housing Co., a globally recognized manufacturer of high-quality modular homes. This new agreement grants Hear At Last the exclusive rights to represent and distribute Hebei Jiachen's affordable modular homes across North Central and America as well as the Caribbean. This str
Household / Consumer / Cosmetics, Health
2025-10-21 8:00 AM EDT | Hear AtLast Holdings, Inc
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-21 7:45 AM EDT | Phio Pharmaceuticals Corp.
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CR
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-10-21 7:27 AM EDT | Cardiol Therapeutics Inc.
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical psychedelics including MDMA and naturally-derived psilocybin, is pleased to announce that it has passed its Drug Establishment Licence (DEL) inspection by Health Canada, with no critical observations, resulting in a GMP-compliant rating for the fabrication and distribution of phar
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-21 7:00 AM EDT | Optimi Health Corp.
TempraMed Announces Private Placement of up to C$2.5 Million
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of up to 3,289,473 units of the Company (each, a "Unit") at a price of C$0.76 per Unit for aggregate gross proceeds of up to C$2,500,000. Each Unit will consist of one common share of the Company (each, a "Share") and one Share purcha
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-21 7:00 AM EDT | TempraMed Technologies Ltd
Cosmo Pharmaceuticals Receives Regulatory Approval by the European Commission for Winlevi(R) in the EU, Following on the Positive CHMP Opinion
Dublin, Ireland--(Newsfile Corp. - October 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Commission has granted regulatory approval in the EU for Winlevi® (clascoterone 1% cream) for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years, with usage in adolescents limited to facial application. This formal approval came following on the po
Healthcare and Hospitals, Health
2025-10-21 1:36 AM EDT | Cosmo Pharmaceuticals N.V.
Glow Lifetech Provides Commercial & Corporate Update; Launches New Key Accounts, Advances National Expansion
Toronto, Ontario--(Newsfile Corp. - October 20, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting new key account wins and expanding national distribution, building on its continued commercial growth. MOD™ Expands to 60+ One Plant Stores in Ontario & Saskatchewan Building on strong commercial momentum with key accounts in Ontario and the Company's recent
2025-10-20 4:15 PM EDT | Glow Lifetech Corp.
Republic Technologies Inc. Announces Up to US$100 Million Proposed Secured Convertible Note Facility Financing
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to announce that it proposes to enter into a financing agreement with an institutional investor (the "Investor") for a proposed secured convertible note facility of up to US$100 million (the "Proposed Convertible Facility") (the "Proposed Financing"), featuring an init
Technology, Pharmaceuticals, Health
2025-10-20 12:59 PM EDT | Republic Technologies Inc.
Republic Technologies Inc. kündigt geplante gesicherte Wandelanleihefazilität in Höhe von bis zu 100 Mio. USD an
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. Oktober 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) ("das Unternehmen" oder "Republic") freut sich bekanntzugeben, dass es beabsichtigt, mit einem institutionellen Investor ("der Investor") eine Finanzierungsvereinbarung über eine geplante gesicherte Wandelanleihefazilität von bis zu 100 Mio. US-Dollar ("die geplante Wandelanleihefazilität") ("die geplante Finanzierung")
Technology, Pharmaceuticals, Health
2025-10-20 9:55 AM EDT | Republic Technologies Inc.
Republic Technologies Inc. Announces Up to US$100 Million Proposed Secured Convertible Note Facility Financing
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to announce that it proposes to enter into a financing agreement with an institutional investor (the "Investor") for a proposed secured convertible note facility of up to US$100 million (the "Proposed Convertible Facility") (the "Proposed Financing"), featuring an initial US
Technology, Pharmaceuticals, Health
2025-10-20 9:20 AM EDT | Republic Technologies Inc.
Rapid Dose Therapeutics Releases Nicotine Business Update and Extends Collaboration with International Nicotine Partner
Burlington, Ontario--(Newsfile Corp. - October 20, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company developing innovative drug delivery solutions through its QuickStrip™ platform, today issued a comprehensive update on its nicotine strategy, including the extension of its exclusive pre-commercialization and development agreement (the "Agreement") with its international nicotine partner. The Agreement,
2025-10-20 8:48 AM EDT | Rapid Dose Therapeutics Corp.